• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Asiatic Acid
Apple Vinegar Powder
Sunitinib Intermediate
Sunitinib Malate Intermediate
Sunitinib Malate
Crizotinib Intermediate

Zydus Cadila get US FDA approval for Atazanavir capsules

expresspharmaJune 08, 2020

Tag: Zydus Cadila , Atazanavir Capsules , FDA

Zydus Cadila has received final approval from the USFDA to market Atazanavir Capsules in the strengths of 150 mg, 200 mg and 300 mg. Atanazavir, an antiretroviral drug, is used to treat infection of the human immunodeficiency virus (HIV).

It is used in combination with other antiretroviral drugs to treat HIV-1 infection. The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.


Previous:Local API production in India for COVID-19 repurposed drugs may offer competitive advantage: GlobalData

Next:Anti-TNF therapies could treat patients with COVID-19-related ARDS

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Zydus Cadila get US FDA approval for Atazanavir capsules | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

HFHA(m-6FDAP)

HFHA(m-6FDAP)
Sirolimus (FDA)

Sirolimus (FDA)
Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)
Vecuronium (FDA)

Vecuronium (FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
Clozapine (FDA)

Clozapine (FDA)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service